- Home
- NIE vs CSTL Comparison
NIE vs CSTL Comparison
Compare NIE & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- CSTL
- Stock Information
- Founded
- NIE 2007
- CSTL 2007
- Country
- NIE United States
- CSTL United States
- Employees
- NIE N/A
- CSTL N/A
- Industry
- NIE Investment Managers
- CSTL Medical Specialities
- Sector
- NIE Finance
- CSTL Health Care
- Exchange
- NIE Nasdaq
- CSTL Nasdaq
- Market Cap
- NIE 697.4M
- CSTL 568.2M
- IPO Year
- NIE N/A
- CSTL 2019
- Fundamental
- Price
- NIE $20.81
- CSTL $21.51
- Analyst Decision
- NIE
- CSTL Strong Buy
- Analyst Count
- NIE 0
- CSTL 6
- Target Price
- NIE N/A
- CSTL $40.00
- AVG Volume (30 Days)
- NIE 70.5K
- CSTL 330.2K
- Earning Date
- NIE 01-01-0001
- CSTL 05-05-2025
- Dividend Yield
- NIE 9.04%
- CSTL N/A
- EPS Growth
- NIE N/A
- CSTL N/A
- EPS
- NIE N/A
- CSTL 0.62
- Revenue
- NIE N/A
- CSTL $332,069,000.00
- Revenue This Year
- NIE N/A
- CSTL N/A
- Revenue Next Year
- NIE N/A
- CSTL $3.34
- P/E Ratio
- NIE N/A
- CSTL $34.69
- Revenue Growth
- NIE N/A
- CSTL 51.09
- 52 Week Low
- NIE $18.61
- CSTL $16.97
- 52 Week High
- NIE $22.47
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- NIE 41.73
- CSTL 56.26
- Support Level
- NIE $20.56
- CSTL $18.03
- Resistance Level
- NIE $21.39
- CSTL $20.77
- Average True Range (ATR)
- NIE 0.79
- CSTL 1.27
- MACD
- NIE 0.05
- CSTL 0.41
- Stochastic Oscillator
- NIE 59.89
- CSTL 93.06
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.